The FDA has approved Prior Approval Supplement To Update Reata Pharmaceuticals's Skyclarys (Omaveloxolone) Drug Substance Specification For Friedreich's Ataxia In Adults And Adolescents, And With This Approval Skyclarys Is Now Available In The US
Portfolio Pulse from Benzinga Newsdesk
The FDA has approved the Prior Approval Supplement for Reata Pharmaceuticals' drug, Skyclarys (Omaveloxolone), for Friedreich's Ataxia in adults and adolescents. With this approval, Skyclarys is now available in the US.
June 28, 2023 | 8:08 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Reata Pharmaceuticals' drug, Skyclarys, has received FDA approval and is now available in the US. This could potentially boost the company's revenues.
The FDA approval of Skyclarys, a drug developed by Reata Pharmaceuticals, means that the drug can now be sold in the US. This could potentially increase the company's revenues as it opens up a new market for the drug. Therefore, this news is highly relevant and important for RETA investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100